|
|
|
|
Lactic acidosis associated with metformin use in treatment of type 2 diabetes mellitus
Metformin, an antihyperglycemic, is widely used in the treatment of type 2 diabetes mellitus (DM). A rare, but important complication associated with this drug is the development of lactic acidosis: Overall mortality of lactic acidosis is approximately 50%. Certain subsets of patients taking metformin are at greater risk of developing lactic acidosis.
|
| |
More>>
|
|
|
|
|
|
New therapies to achieve glycemic control and weight loss in T2DM
Today's management of type 2 diabetes mellitus is supported by an array of therapeutic agents, including new drugs approved in 2005 that can promote weight loss along with glycemic control—pramlintide and exenatide—and an inhaled insulin, which was approved in 2006.
|
| |
More>>
|
|
|
|
|
|
Consider metabolic syndrome a combination of different conditions
No wonder metabolic syndrome is called syndrome X. Instead of being recognized as a separate disease, it is considered a constellation of many conditions. "The biggest problem is a failure to address the underlying problem—insulin resistance," says Robert Epstein, MD, chief medical officer for Medco Health Solutions in Franklin Lakes, N.J. He calls metabolic syndrome one of the country's top five health problems.
|
| |
More>>
|
|
|
|
|
|
Global guidelines launched for Type 2 diabetes
The International Diabetes Federation (IDF) launched the first global evidence-based guidelines for Type 2 diabetes at the September meeting of the European Association for the Study of Diabetes, in Athens. Diabetes afflicts more than 194 million people worldwide. "Estimates and projections agree that the number of diabetes cases that may be reached in the next 25 years would qualify as the largest epidemic humanity has ever experienced," said Philip Home, joint chair of the IDF Task Force on Clinical Guidelines.
|
| |
More>>
|
|
|
